Junshi Biologics subcutaneous injection preparation JS001sc injection clinical application is accepted

On December 23, Junshi Biotech announced that JS001sc injection has obtained the notification of acceptance of drug clinical trial applications
.
JS001sc injection is a subcutaneous injection preparation developed by the company on the basis of the already marketed product Teriprizumab injection (trade name: Tuoyi?, product code: JS001)
.
JS001sc targets human PD-1, binds to PD-1 with high affinity, and selectively blocks the binding of PD-1 to the ligands PD-L1 and PD-L2, thereby activating T lymphocytes and improving the proliferation and cell proliferation of lymphocytes.
Secretion of factors
.
Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
At a dose level of 0.
3 mg/kg, JS001sc administered by subcutaneous injection and Terry administered by intravenous injection The anti-tumor effect of prilimumab was equivalent, and no significant difference was seen
.
In addition, the animals have a good tolerance to JS001sc
.
With the gradual popularization of the concept of "chronic disease management" in tumor immunotherapy, compared to frequent visits to the hospital for several hours of intravenous injection, shorter time subcutaneous injections are more attractive
.
At the same time, subcutaneous injection can avoid infusion-related adverse reactions caused by intravenous administration, benefit the patient as a whole, and reduce medical costs
.
After inquiring about public information, as of the disclosure date of this announcement, among the more than ten PD-(L)1 antibodies that have been marketed worldwide, only Envolimab injection (trade name: Envida?) is injected subcutaneously.
Medicine, other products are administered intravenously
.